Showing posts with label Digital Rectal Exam. Show all posts
Showing posts with label Digital Rectal Exam. Show all posts

Tuesday, May 07, 2013


Digital rectal exam remains important part of prostate screening

07may 2013—The digital rectal exam is an important screening test that can discover prostate cancer that a prostate-specific antigen or PSA test may not, despite the higher sensitivity of the PSA test, according to Penn State College of Medicine researchers.
The digital rectal examination is a procedure where a physician feels the surface of the prostate with a gloved finger. The doctor is able to feel any lumps or hard areas on the prostate.
A PSA test checks for levels of prostate-specific antigen in the blood, with higher levels signaling potential cancer. As men age, the acceptable PSA level increases.
"Prostate cancer is the most common cancer in men, accounting for over 28,000 deaths yearly," said Jay Raman, M.D., associate professor of surgery. "Improvements in screening methodology and refinements in cancer care have contributed, in part, to a reduction in recent mortality rates."
An elevated PSA level or an abnormality found on the prostate during the digital rectal exam typically leads to the recommendation of prostate needle biopsy, the most accurate diagnostic technique. Elevated PSA levels have been shown to more accurately predict a positive cancer biopsy result than the rectal exam. The digital rectal exam has been considered less precise because of the variability in of who is administersing the test and the experience of that person, and the incorrect positives associated with noncancerous abnormalities.
Other studies have shown the PSA test to be more sensitive and specific than the digital rectal exam, especially at low PSA levels. However, no study to the researchers' knowledge has looked at the effectiveness of the digital rectal exam when compared to age-adjusted PSA levels.
Penn State Hershey researchers studied 806 men from September 2001 to December 2008 to see how the initial testing lined up with the results of their biopsies.
In the group of men studied, half had elevated PSA levels and 36 percent had an abnormal digital rectal exam (with or without an elevated PSA). The biopsy diagnosed 306 of the men as having prostate cancer. Of that number, 136 of the men had an abnormal digital rectal exam finding.
Most importantly, 43 of the 136 men who had an abnormal digital rectal exam showed a normal PSA level for their age. While 14 percent of all patients with prostate cancer had an abnormal digital rectal exam, 31 percent of these men had normal PSA levels for their age.
"It is important to acknowledge that age-specific PSA cutoffs contribute some limitations in prostate cancer screening," Raman said. "In particular, while age-specific thresholds increase the sensitivity in younger men, these same cutoff values lower the sensitivity in older men."
Because the acceptable PSA level is increased for older men, it is possible that prostate cancer is being missed if only the PSA test is used.
"Our study confirms that the digital rectal exam remains an important part of screening such patients because 31 percent of cancers in our study would have been missed by using age-specific PSA cutoffs alone," Raman said.
Researchers published their findings in The Canadian Journal of Urology.
Provided by Pennsylvania State University

Sunday, June 21, 2009

Digital Rectal Exam Remains Key in Men With Low PSA

Digital rectal exam findings are suspicious for cancer in many with PSA less than 2.5

21 june 2009-- Due to the number of men who may have aggressive prostate cancers despite a low prostate specific antigen (PSA), digital rectal exams (DREs) remain important in detecting early cancer, according to research published in the June issue of the Journal of Urology.

Joshua J. Meeks, M.D., of the Northwestern Feinberg School of Medicine in Chicago, and colleagues analyzed data from 77 patients who underwent radical retropubic prostatectomy and had a preoperative PSA less than 2.5 ng/ml.

The researchers found that in 66 percent of these men with low PSA, DRE findings were suspicious for cancer. The Gleason sum was 7 or higher in 10.4 percent of the men at biopsy and 26 percent of the men at surgery. Nine percent of patients had extracapsular tumor extension, and nearly 7.8 percent had positive surgical margins. The authors further note that mean tumor volume was significantly higher in men with a suspicious DRE compared to a normal exam (3.3 versus 1.7 cc).

"This study confirms that if we hope to detect some of these cancers without even an intermediate PSA increase, DRE can be a potent tool to detect clinically significant cancers in referral populations. The authors reported that adverse pathological features were observed significantly more frequently in patients with an abnormal DRE than in those with a normal DRE," writes the author of an accompanying editorial.

A study co-author reported a relationship with Beckman Coulter Inc., which supported the study, and deCODE Genetics.

Abstract
Full Text (subscription or payment may be required)
Editorial